Kornimate/medical-research-clean huggingface dataset:
patient's whole process follow-up management(hope-1)

Conditions: Locally Advanced Non-Small Cell Lung Cancer; Metastatic NSCLC

Summary: our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

now, the treatment of nsclc is diversiform, such as radiation and chemotherapy, targeted therapy, immune therapy, the treatment goal is to reduce symptoms, improve quality of life, prolong life. but as a result of the disease itself has the high risk of metastasis and recurrence. the treatment is often accompanied by a series of complications, if the patients don't get medical assistance in time, it will lead high risk to physical and mental health of patients. in china, the intermittent period of domestic treatment is mainly family recuperation, but due to the lack of medical knowledge or self-management and self-restraint ability of patients, they may forget to take medicine, stop medication without permission due to side effects and other behaviors that do not follow the doctor's advice, the poorly patients' compliance will lead to a significant reduction in the treatment effect. nsclc are often accompanied by anxiety, fear, insomnia and other symptoms, causing a huge psychological burden on patients and their families, affecting the quality of life. whole process follow-up in tumor therapy plays an important role , it is the crucial link between medical, nursing, and patients. patients' whole process follow-up and management is an important part of cancer disease management. it is helpful to relieve the patients and their families of the bad psychology, reduce the symptoms of patients, improve the patient's compliance behavior, relieve the psychological anxiety of patients, make it actively cooperate with the treatment, reduce complications, improve the quality of life of patients, so as to prolong the life cycle. our project is going to explore whether management and follow-up of locally advanced/metastatic patients using the patient process management platform can prolong patient survival and improve patient quality of life.

Eligibility criteria:
inclusion criteria: 1. fully understand the research and voluntarily sign the informed consent form (icf) 2. male or female subjects who are over 18 years old (inclusive) at the time of signing the informed consent form. 3. the subject is diagnosed pathologically or cytologically with non-small cell lung cancer(nsclc). 4. according to the 8th edition of the american joint committee on cancer \[ajcc\], it is classified as stage iib, stage iii, stage iv nsclc. 5. not suitable for radical treatment or refuse surgery. 6. the life expectancy is not less than 3 months. 7. be able to use a smartphone. exclusion criteria: 1. patients with mental illness. 2. presence of any other malignant tumor. 3. patients who are expected to undergo radical surgery. 4. currently participating in clinical trials. 5. subjects who judged by the investigator to be unsuitable to participate in the trial.
respiratory kinematics during voluntary and reflex cough in healthy adults

Conditions: Cough

Summary: cough is a defensive behavior that involves three stages. a large inspiratory phase, a compression phase where the vocal folds close and subglottal pressure is developed, and an expiratory phase. cough serves to protect the upper and lower airways from material such as liquids, solids, or saliva, that have been aspirated. there are two types of cough: voluntary and reflex cough. voluntary cough involves a cough to command. reflex cough is a cough that is generated secondary to a stimulus in or near the airway. there has been some research regarding the differences between voluntary and reflex cough. however, no research has described the differences in airflow or movement pattern (kinematics) between the two types of cough. this study seeks to determine the respiratory kinematics and airflow differences between voluntary and reflex cough in healthy participants.

as a participant, completion of this study will require the following: investigators will first place cotton elastic bands around your chest and abdomen so that measures of chest wall and abdominal movements can be measured. then, tests of your breathing made from pulmonary function testing will be completed. investigators will then have you complete a maximum inspiration followed by a maximum expiration three times. investigators will ask you to produce a voluntary cough three times into a facemask which is attached to a computer. then the investigators will provide you with nebulized water (fog) through the facemask for up to a minute three times. you will have a minute break in between each presentation. finally, the investigators will provide you with a nebulized dose of capsaicin, which is derived from hot peppers, through the same facemask used in all of the above tasks. you will receive three doses of capsaicin and be provided with water at any time during the study.

Eligibility criteria:
inclusion criteria: * healthy adults between the ages of 18-80 years. * ability to provide informed consent. exclusion criteria: * no history of smoking within the last 5 years as this reduces the sensitivity to capsaicin * no history of neurological disease (i.e. parkinson's disease, stroke, traumatic brain injury, etc.) * no known allergy to capsaicin * no history of respiratory disease (i.e. asthma, chronic obstructive pulmonary disease, or respiratory infection within the last 5 weeks.)

Keywords: cough
a study of pegylated liposomal doxorubicin and cyclophosphamide in her2-negative stage i and ii breast cancer patients

Conditions: Breast Cancer

Summary: primary objective: * to evaluate the disease-free survival (dfs) in the two randomized arms after therapy with lc vs. ec in chemo-naive her2-patients with stage i or ii breast cancer secondary objectives: * to assess the overall survival (os) * to establish the safety profile by assessing the toxicities and tolerability * to assess the quality of life (qol) * to evaluate survival correlation with biomarkers expression.


Eligibility criteria:
inclusion criteria: * histologically confirmed invasive, but non-inflammatory, breast adenocarcinoma with stage i or ii (if n0, t must be \>1cm) disease * her2-negative on fluorescence in situ hybridization (fish) study * performance status of ecog 0, 1 * female, age between 20 and 70 years * life expectancy of at least one year * ability to understand and willingness to sign a written informed consent document exclusion criteria: * her2 3+ over-expression on immunohistochemistry (ihc), or her2 amplification on fluorescence in situ hybridization (fish) study * previous or current systemic malignancy with the exception of curatively treated non-melanoma skin cancer or cervical carcinoma in situ, unless there has been a disease-free interval of at least 5 years * patients who have received prior chemotherapy * inadequate hematological function defined as absolute neutrophil count (anc)less than 1,500/mm3, and platelets less than 100,000/mm3 * inadequate hepatic function defined as: serum bilirubin greater than 1.5 times the upper limit of normal range (uln) alanine aminotransferase (alt) or aspartate aminotransferase (ast) greater than 2.5 times the uln * inadequate renal function defined as serum creatinine greater than 1.5 times the uln * left ventricular ejection fraction (lvef) \< 50% confirmed by multiple-gated acquisition (muga) scan or echocardiogram * concomitant illness that might be aggregated by chemotherapy or interfere study assessment. for examples, active, non- controlled infection (such as hepatitis b and hepatitis c, hiv, infectious tuberculosis) or other active, non-controlled disease such as congestive heart failure, ischemic heart disease, uncontrolled hypertension or arrhythmia, unstable diabetes mellitus, and active peptic ulcer * patients who are presence of liver cirrhosis or are hbv/hcv carrier * participation in another clinical trial with any investigational drug within 30 days prior to entry * pregnant or breast feeding women * fertile women of child-bearing potential unless using a reliable and appropriate contraceptive method throughout the treatment period and for three months following cessation of treatment

Keywords: phase ii pegylated liposomal doxorubicin adjuvant chemotherapy breast cancer
evaluation of pcd-ct based image parameters in the assessment and quantification of coronary artery disease

Conditions: Coronary Artery Disease

Summary: the goal of this observational study is to learn about a new type of computed tomography (photon-counting detector ct) in patients with coronary artery disease. the main questions it aims to answer are: * how good is the image quality for the new ct * how accurate are measurements in the images of the new ct * is there a relationship between measurements in the images and the management of the disease (e.g. new medication or additional investigations) * is there a relationship between measurements in the images and the results of follow-up investigations * is there a relationship between measurements in the images and the patient outcome participants will undergo normal clinical assessment of coronary artery disease and all data from the ct scan and additional investigations will be collected. there will be no additional investigations for the purpose of the study. after 1, 2 and 5 years, participants will be asked to answer a health questionaire.


Eligibility criteria:
inclusion criteria: * clinical indication for a coronary computed tomography angiography (ccta) for the suspicion of coronary artery disease or the progression thereof * written informed consent exclusion criteria: * contraindications preventing the execution of the ccta (e.g., pregnancy)
frozen shoulder (scapular mobilization versus scapular pnf)

Conditions: Frozen Shoulder; Scapular Mobilization; Scapular Proprioceptive Neuromuscular Facilitation

Summary: this study will be conducted to examine and compare the effects of sm versus spnf on shoulder pain, rom and functional disabilities in patients with frozen shoulder.

this study will be conducted to examine and compare the effects of sm versus spnf on shoulder pain, rom and functional disabilities in patients with frozen shoulder.

Eligibility criteria:
inclusion criteria: - all the patients refferd from orthopaedic surgeon with diagnosis of adhesive capsulitis. patients will be included in this study if they fulfil the following criteria 1. case diagnosed with adhesive capsulitis, both primary and secondary. 2. both males and females of the age group 40 to 60 years. 3. limited active and passive movement of the shoulder joint movements, as well as difficulties with adls. 4- the onset of symptoms between 3 to 12 months. 5. unilateral adhesive capsulitis. exclusion criteria: * 1. history of shoulder surgery or manipulation under anaesthesia, local corticosteroid injection administration to the affected shoulder within the last 6 months, 2. neurological deficit affecting the shoulder function during daily activities, 3. pathology of the shoulder joint other than adhesive capsulitis including rotator cuff tear, tendonitis at the shoulder and neck region, malignancies, history of trauma or accidental injuries of the upper limb. 4- other pathological conditions including, a history of stroke, history of mastectomy and coronary artery bypass grafting (cabg). 5. rheumatoid arthritis, osteoporosis, or disorders of the cervical spine, elbow, wrist or hand.
90yttrium colloid for the treatment of cystic sellar/parasellar tumors

Conditions: Cystic Tumors of the Sellar/Parasellar Region

Summary: there is no consensus in the literature on the best way to treat cystic lesions of the pituitary area. patients who are symptomatic from these tumours are rare. the cystic form of tumours present special challenges since traditional treatment modalities (surgery and/or external radiation) are often not able to completely remove or treat the cyst wall without major morbidity or even mortality. there is no 'best practice' for the treatment of cystic tumours per se. treatments available to patients with cystic sellar/parasellar tumours include conservative management using a 'wait and scan' approach, cyst drainage, and cyst removal via transsphenoidal and/or craniotomy approach (i.e. open surgery). over the last 10 years we have treated approximately 8 patients with intracystic radiotherapy. all of these patients continue to be monitored clinically and radiologically and all have done well with stable regression of the cysts and no new neurological deficits. over the past 2 years, 90yttrium colloid has been provided to cdha through health canada's special access program (sap). it has only been of recent that health canada has requested a clinical trial to assess the benefit of intracystic radiotherapy over other available treatment options. the experimental treatment being proposed is the stereotactic intracavitary instillation of 90yttrium colloid for treatment of cystic lesions of the pituitary (sellar) and surrounding areas (parasellar).

surgical procedures will be performed as standard of care. the treating neurosurgeon (dr. david b. clarke) will determine surgical parameters based on his clinical expertise.

Eligibility criteria:
criteria ages eligible for study: 17 years of age or older genders eligible for study: both accepts healthy volunteers: no inclusion criteria patients who meet all of the following criteria are eligible for enrollment as study participants: 1. patients 17 years of age or older. 2. cystic sellar, suprasellar, parasellar or intrasellar masses diagnosed by histology, cytology or neuroimaging. 3. tumour measurements and/or tumour volume can be calculated. 4. patients who require surgical intervention as determined by the treating neurosurgeon. 5. being a patient managed in the halifax neuropituitary program surgical clinic. 6. willingness to undergo surgery and give informed surgical consent. 7. willingness to provide informed consent for study participation. exclusion criteria patients who meet any of these criteria are not eligible for enrollment as study participants: 1. neurosurgeon's assessment that surgical procedures hold unacceptable operative risk. 2. having a solid tumour. 3. pregnant or breast feeding at time of surgical consent and/or surgery. 4. hypersensitivity, allergies or contraindication to the used radiopharmaceutical agent (90yttrium colloid).

Keywords: rathke's cleft cyst, pituitary cysts cystic craniopharyngiomas
clinical validation of a predictive test for postpartum depression

Conditions: Postpartum Depression (PPD); Pregnancy

Summary: the goal of this observational study is to develop a blood test that may be predictive of postpartum depression. this blood test is investigational and not yet fda approved. participants will not receive the results of this blood test. up to 500 pregnant women will be recruited for the study from 2 sites. participants must be age 18 or above with a singleton pregnancy and able to provide written consent in english. the objective of this clinical trial is to prospectively validate the enlighten device test by prospectively determining false/true positive and negative rates. building off of this, an exploratory objective of this study is to examine clinical factors associated with false positive/negative rates. this project will address the following aim: aim 1: prospective collection of true/false positive and negative ppd outcomes through 6 months postpartum. primary hypothesis h1a: 80% or greater of pregnant women who develop ppd by 3 months after delivery will be determined to be biomarker positive by the enlighten device in t3. primary hypothesis h1b: 10% or fewer of pregnant women who are determined to be biomarker negative by the enlighten device in t3 will develop ppd by 3 months after delivery. exploratory aim 1: investigation of clinical factors that may be associated with false positive and false negative rates, such as: medication use, stressful life events, and sociocultural context. participants will be screened during the second or third trimester and enrolled during the third trimester, before week 30 weeks of gestation. participants may self- identify through study advertisements in participating clinics, social media outlets, and community outreach efforts. enrolled participants will undergo blood collection during their 3rd trimester (\~27-30 weeks, a standard pregnancy-related blood collection timepoint) for completion of the enlighten device test, the blood-based epigenetic biomarker test. participants will then be interviewed at 2 weeks, 6 weeks, 3 months, and 6 months postpartum for the development of depression symptoms. they'll also complete a multitude of other outcome measures at each of these visits.


Eligibility criteria:
inclusion criteria: * subject must be pregnant (singleton pregnancy) * \<30 weeks' gestation, age 18 or above * able to provide written consent in english exclusion criteria: * the study team and/or pi may exclude anyone deemed unsafe to participate in the protocol.

Keywords: pregnancy postpartum depression predictive test blood test third trimester
lung cancer patients' attitudes to a second course of radiotherapy

Conditions: Lung Cancer; Recurrence

Summary: patients with lung cancer are often treated with high dose x-ray treatment (radical radiotherapy) to control the disease. after one course of radiotherapy, after a period of time, there is a risk that the cancer can come back in either the same place or nearby in the lungs. this happens to about 700 patients in the uk every year. there is no strong evidence to suggest what the best treatment is in this situation. one possible treatment is a second course of radiotherapy (re-irradiation). early studies show that a re-irradiation may cause significant side effects like breathlessness or problems swallowing, but may control the cancer for a long period of time. we want to do a clinical trial to investigate if re-irradiation improves cancer control compared to other treatments to help guide treatment for patients with recurrent disease. before we can go ahead with the trial, we would like to talk to patients who are have completed radiotherapy to find out what are their feelings about having a second course of radiotherapy if needed, and how the side effects from the initial course of radiotherapy or the projected side-effects from the second course would affect that decision. this information is vitally important to help develop a trial about re-irradiation in lung cancer as it will demonstrate if patients would accept a second course of radiotherapy, and, by accounting for patient concerns in the trial design, will make it more likely to recruit well. this study will perform telephone interviews with patients five weeks after completing a course of radical radiotherapy for lung cancer at the beatson cancer centre. we expect to interview 16-30 patients. this study will run over the course of 1 year. this research is funded by the beatson cancer charity and the university of glasgow.


Eligibility criteria:
inclusion criteria: * age 18 years old or above * pathological or radiological diagnosis of non-small cell lung cancer * undergoing radical radiotherapy to the thorax using the following fractionations (55 gray in 20 fractions, 54 gray in 36 fractions or any stereotactic ablative body radiotherapy (sabr) fractionation that delivers a biological effective dose of greater than 100gy10) as part of their primary lung cancer treatment at time of study enrolment * patients receiving concurrent and/or adjuvant systemic therapies are permitted * radiotherapy is delivered in the beatson west of scotland cancer centre * signed, written informed consent * willing and able to complete study processes exclusion criteria: * not fluent in english
detection of bacteria in herniated nucleus material in lumbar disc herniations by culture and pcr

Conditions: Lumbar Disc Herniations

Summary: the aim is to investigate if herniated nucleus material in lumbar disc herniations is infected with bacteria, and if so, to determine their prevalence (control group), and to determine if patients with pre-existing modic changes type 1 have a higher incidence of bacterial growth in relevant lumbar disc samples than patients without modic changes. a cohort of 15 patients with pre-existing modic and 15 without-undergoing primary surgery will be examined.

the nucleus material will be evacuated and divided into 5 biopsies, each with a new set of sterile instruments and placed in separate sterile glass vials with one drop of sterile saline to prevent drying of biopsy. the primary outcome, i.e., bacterial growth on a per-patient basis. bacterial growth shall be detected in minimum 3 out of 5 biopsies for the patient to be scored as positive for bacteria.

Eligibility criteria:
inclusion criteria: * mri-confirmed lumbar disc herniation. * age between 18 and 65 years. * no prior spine surgery. * no diagnosed dementia. exclusion criteria: * antibiotic treatment within the previous two weeks. * history of alcohol abuse, illicit drug use or drug abuse, or significant mental illness * known immune deficiency state (e.g., positive for human immunodeficiency virus) or in treatment with immunosuppressive drugs including high dose steroids or cyclosporine. * concurrent infections (infections of skin, urinary tract infection, other skin diseases, e.g. acne vulgaris). * previous epidural instrumentation. * uncontrolled, unstable or recently diagnosed autoimmune disease, including but not limited to systemic lupus erythematosus, inflammatory bowel disease, sarcoidosis, rheumatoid arthritis, or psoriasis.

Keywords: modic microbiology immunology
evaluation of efficacy and safety of meloxicam suppository (15mg daily) and tablet (15 mg daily) compared to indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis

Conditions: Spondylitis, Ankylosing

Summary: study to assess the efficacy and safety of meloxicam suppository 15 mg once daily, meloxicam tablet 15 mg once daily compared with indomethacin suppository (50 mg daily) in patients with ankylosing spondylitis


Eligibility criteria:
inclusion criteria: * active ankylosing spondylitis (pain rated \>= 40 mm on a vas and increased of at least 30% after nonsteroidal anti-inflammatory drugs (nsaids) wash-out)), without peripheral arthritis and inflammatory bowel disease exclusion criteria: * none